NUMIF

Numinus Wellness Inc.

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

VANCOUVER, BC, Dec. 13, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS" or "MAPS PBC") for its submission of a new drug a... Read More...

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023

VANCOUVER, BC, Aug. 9, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at... Read More...

Numinus Appoints New Chief Financial Officer

VANCOUVER, BC, June 14, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executi... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023

VANCOUVER, BC, June 2, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June... Read More...

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

First Numinus Network™ partner enters into agreement Recent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy e... Read More...

Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research

New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy. Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety. VANCOUVER, BC, Dec. 8, 2022 - Numinus Wellness ... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

VANCOUVER, BC, Nov. 22, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, Dece... Read More...

Miami on November 3-5, 2022

 VANCOUVER, BC, Oct. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Cent... Read More...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

VANCOUVER, BC, Oct. 7, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thur... Read More...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

Numinus provides update on acquisition integration and announces new client financing options

US clinics acquired from Novamind demonstrating continued growth Physical rebranding of clinics is underway Announcing new client financing options in Canada VANCOUVER, BC, Sept. 13, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) ( OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acqu... Read More...

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

VANCOUVER, BC, Aug. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte ... Read More...

Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

VANCOUVER, BC, June 21, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New Yor... Read More...

Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind

Novamind shareholders, at a separate meeting held today, have also approved the transaction Transaction expected to be completed on or about June 10, 2022 VANCOUVER, BC, June 8, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to... Read More...

Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Ca... Read More...

Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

VANCOUVER, BC, May 11, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.... Read More...

Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders

VANCOUVER, BC, Feb. 28, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earli... Read More...

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

The trial evaluates Numinus' first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally submitted the clinical trial application ("CTA") to Health Canada for its... Read More...

Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders

VANCOUVER, BC, Jan. 13, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 20... Read More...

Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines

Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis VANCOUVER, BC, Dec. 22, 2021 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, commends Health Canada's leadership for amending th... Read More...

Numinus Announces Departure of Stacey Wallin

VANCOUVER, BC, Nov. 25, 2021 - Numinus Wellness Inc. ("Numinus") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with t... Read More...